跳至主要内容
临床试验/JPRN-UMIN000032022
JPRN-UMIN000032022招募中未知

Efficacy and safety of corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a prospective randomized multicenter clinical trial - Corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for anti-ARS antibody-positive PM/DM-ILD

Hamamatsu University School of Medicine0 个研究点目标入组 66 人开始时间: 2018年4月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who meet the following criteria are excluded from this study: (1) Patients who requires systemic high dose corticosteroid, immunosuppressants, intravenous immunoglobulin therapy, plasma exchange, or biologic agents for a disease other than PM/DM/CADM-ILD at the registration (2) Patients with severe respiratory failure (PaO2 < 50 Torr) (3) Patients with contraindication of prednisolone or tacrolimus (4) Patients with a serious comorbidity (e.g. advanced malignancy, imminent aortic aneurysm, and Liver cirrhosis) (5) Patients with anti-MDA5 antibody (6) Patients who are judged unqualified for this study by attending physician

研究者

相似试验